RenovoRx, Inc.RNXT
Price (close)
$1.68
Market cap
$75.8M
P/E
—
Revenue (TTM)
$2.0M
Net income
-$12.3M
Dividend yield
—
1-year total return
43.6%
Net margin
-621.7%
Revenue growth
—
Debt / equity
—
What RenovoRx, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $43,000 | $1.1M |
| Net income | -$3.8M | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M |
| Free cash flow | — | — | — | — | -$9.1M | -$11.0M |
More on RNXT.
- RenovoRx, Inc. summary
- RenovoRx, Inc. financial statements
- RenovoRx, Inc. key metrics
- RenovoRx, Inc. health scores and style box
- RenovoRx, Inc. earnings
- RenovoRx, Inc. dividends
- RenovoRx, Inc. valuation
- RenovoRx, Inc. ownership and insiders
- RenovoRx, Inc. peers
Figures from RenovoRx, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.